Dosing considerations for inhaled biologics

Silvia Ferrati; Tian Wu; Sekhar R Kanapuram; Hugh D C Smyth

doi:10.1016/j.ijpharm.2018.07.054

Dosing considerations for inhaled biologics

Int J Pharm. 2018 Oct 5;549(1-2):58-66. doi: 10.1016/j.ijpharm.2018.07.054. Epub 2018 Jul 24.

Authors

Silvia Ferrati¹, Tian Wu², Sekhar R Kanapuram², Hugh D C Smyth³

Affiliations

¹ The University of Texas in Austin, Division of Molecular Pharmaceutics and Drug Delivery, Austin, TX, USA.
² Amgen Inc., Thousand Oaks, CA, USA.
³ The University of Texas in Austin, Division of Molecular Pharmaceutics and Drug Delivery, Austin, TX, USA. Electronic address: hugh.smyth@austin.utexas.edu.

PMID: 30053488
DOI: 10.1016/j.ijpharm.2018.07.054

Abstract

The number of biologics in the therapeutic development pipeline is increasing including those delivered though inhalation (Morales, 2017; Fathe, 2016). Biologics comprise a broad variety of complex macromolecules with unique physicochemical characteristics. These distinctive characteristics control their pharmacological mechanisms of action, stability, and ultimately affect their processing, formulation, and delivery requirements. This review systematically covers crucial aspects of biologic powders formulations and dry powder inhalers which need to be taken into consideration to establish the drug loading and the payload to be delivered to reach the desired clinical dose.

Keywords: Biologics; Devices; Dry powder inhalers; Formulation drug loading.

Publication types

Review

MeSH terms

Administration, Inhalation
Animals
Biological Products / administration & dosage*
Biological Products / pharmacology
Chemistry, Pharmaceutical / methods*
Dose-Response Relationship, Drug
Drug Delivery Systems*
Dry Powder Inhalers
Humans

Substances

Biological Products